Medtronic Collects Data To Support Reduced Follow Up For Endurant AAA Graft
This article was originally published in The Gray Sheet
Executive Summary
The company expects its postmarket data to show that the Endurant abdominal aortic aneurysm graft is so reliable that, at least for some patients, routine follow-up can be less frequent than is currently recommended in professional guidelines.
You may also be interested in...
Research Briefs: Reports On HeartMate II Thromboses, Endurant AAA Graft Durability,Corus CAD Test
Three major teaching hospitals are reporting an unexpected increase in thrombosis in patients implanted with HeartMate II left ventricular assist devices since March 2011. More research news.
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.